Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Motavizumab Second Season Dosing in Children
NCT00113490Phase 2Completed
- Sponsor
- MedImmune
- Start
- May 2005
- Primary completion
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of motavizumab in respiratory syncytial virus infection (RSV) (2 arms), sponsored by MedImmune. Primary endpoint: Number of Subjects Exhibiting Anti-motavizumab Antibodies. Started May 2005; status: completed.
02
Drugs
motavizumab
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00113490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113490.